B02BX · Blood and blood-forming organs
Mulpleo (previously Lusutrombopag Shionogi)
Indications
Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
Composition
- Active substance
- Lusutrombopag
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mulpleo (previously Lusutrombopag Shionogi)
- Active substance
- Lusutrombopag
- ATC code
- B02BX
- Therapeutic area
- Thrombocytopenia
- Marketing authorisation holder
- Shionogi B.V.
- Status
- Authorised
- EU authorisation
- 18 Feb 2019